Table 1.

Inhibitory concentration (IC₅₀) values of cancer cell lines in response to NAE inhibitors SOMCL-19-133 and MLN4924 treatments.

No.	Cell lines	Types	IC50 (mean ± SD) (nM)		IC50 (4924)/ IC50 (S133)
			SOMCL-19-133	MLN4924
1	THP-1	Leukemia	33.59 ± 8.48	60.15 ± 32.24	1.79
2	MV-4-11	Leukemia	40.83 ± 2.21	121.17 ± 1.79	2.97
3	Jurkat, Clone E6-1	Leukemia	70.43 ± 6.19	283.83 ± 95.63	4.03
4	NOMO-1	Leukemia	159.29 ± 23.33	626.87 ± 77.82	3.94
5	KG-1	Leukemia	204.37 ± 53.17	935.65 ± 257.77	4.58
6	SW48	Colon cancer	5.59 ± 1.16	79.54 ± 23.09	14.23
7	COLO 205	Colon cancer	8.75 ± 1.69	54.23 ± 2.47	6.20
8	HCT-116	Colon cancer	15.71 ± 3.78	60.78 ± 11.74	3.87
9	HT-29	Colon cancer	40.22 ± 8.54	296.27 ± 32.30	7.37
10	RKO	Colon cancer	40.23 ± 5.12	150.50 ± 26.38	3.74
11	HCT 15	Colon cancer	56.88 ± 20.93	293.65 ± 80.29	5.16
12	SW480	Colon cancer	732.48 ± 258.11	1091.82 ± 91.73	1.49
13	SW620	Colon cancer	2164.76 ± 221.23	5552.47±2367.56	2.56
14	Capan-1	Pancreatic cancer	9.44 ± 0.95	96.48 ± 10.06	10.22
15	MIA PaCa-2	Pancreatic cancer	17.98 ± 3.18	108.77 ± 16.05	6.05
16	SUIT-2	Pancreatic cancer	29.22 ± 7.63	203.71 ± 29.05	6.97
17	Panc 02.03	Pancreatic cancer	97.25 ± 5.67	355.91 ± 39.08	3.66
18	HGC-27	Gastric cancer	22.03 ± 7.44	98.53 ± 28.33	4.47
19	NCI-N87	Gastric cancer	65.08 ± 24.18	864.58 ± 77.52	13.28
20	DU 145	Prostate cancer	12.55 ± 2.79	86.45 ± 15.13	6.89
21	LNCaP	Prostate cancer	15.24 ± 0.99	52.48 ± 13.36	3.44
22	PC-3	Prostate cancer	962.55 ± 624.98	2434.10 ± 1046.08	2.53
23	TOV-112D	Ovarian cancer	66.00 ± 39.15	228.76 ± 103.56	3.47
24	OVCAR-8	Ovarian cancer	127.15 ± 15.72	540.59 ± 64.15	4.25
25	CHL-1	Melanoma	128.53 ± 19.75	320.46 ± 121.92	2.49
26	G-361	Melanoma	272.36 ± 182.09	1427.71 ± 683.93	5.24
27	NCI-H1975	NSCLC	108.47±22.77	ND	NA
28	NCI-H226	NSCLC	124.18 ± 62.36	1035.87 ± 624.15	8.34
Average			201.11	646.72	5.31